Progenity Provides Corporate Update and Reports First Quarter 2021 Financial Results
May 13, 2021 16:03 ET
|
Progenity, Inc.
Reports revenues of $24.5 million in the first quarter of 2021, up 72% from prior quarter Announced pre-validation data for its Preecludia™ test showed strong performance consistent with...
Progenity Provides Preliminary Results from Key Studies for its Targeted Therapeutics Program
May 12, 2021 07:29 ET
|
Progenity, Inc.
SAN DIEGO, May 12, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced preliminary results, subject to final audited study reports by its...
Global Stoma/Ostomy Care Market 2020: Market is Projected to Reach US$3.8 Billion by the year 2027, Trailing a Post COVID-19 CAGR of 4.2%
December 07, 2020 05:18 ET
|
Research and Markets
Dublin, Dec. 07, 2020 (GLOBE NEWSWIRE) -- The "Stoma/Ostomy Care - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Focus on Stoma Quality of...
Pandion Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
November 16, 2020 16:01 ET
|
Pandion Therapeutics, Inc.
- Enrollment and dosing complete in Phase 1a clinical trial of PT101; top-line results expected early 2021- PT627 systemic PD-1 agonist development candidate nominated; IND-enabling studies expected...
Innovation Pharmaceuticals Plans for Phase 2 Trial of New Treatment for Ulcerative Colitis
March 05, 2020 08:00 ET
|
Innovation Pharmaceuticals Inc.
Active ulcerative colitis targeted; multiple ascending dose design (low, mid, high doses and placebo)Endpoints: clinical remission (Mayo scoring); endoscopic remission; biomarkers, and others ...
Innovation Pharmaceuticals Phase 1 Trial of Brilacidin for Ulcerative Colitis Meets Primary Endpoints; Positive Topline Results of Oral Brilacidin
February 13, 2020 10:00 ET
|
Innovation Pharmaceuticals Inc.
Targeted colonic delivery shownDrug well-tolerated WAKEFIELD, Mass., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical...
Innovation Pharmaceuticals Completes Dosing in Phase 1 Trial for New Oral Ulcerative Colitis Drug
January 24, 2020 11:30 ET
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., Jan. 24, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, announced today the Company completed dosing in...
Innovation Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Trial of Oral Brilacidin in Ulcerative Colitis Program; Topline Results Anticipated Early Q1 2020
January 16, 2020 12:00 ET
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., Jan. 16, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform shareholders that the...
Innovation Pharmaceuticals: Patient Screening for Phase 1 Trial of Oral Brilacidin in Ulcerative Colitis Program On Track for Early January
December 26, 2019 08:00 ET
|
Innovation Pharmaceuticals, Inc.
Patient screening positions Company for completion of a short clinical trialSignificant market demand for oral drugs in Inflammatory Bowel DiseaseBusiness development meetings scheduled during 2020...
Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in a New Study for Crohn’s Disease
December 03, 2018 07:00 ET
|
Breathtec Biomedical Inc.
VANCOUVER, British Columbia, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI)...